<DOC>
	<DOCNO>NCT03003949</DOCNO>
	<brief_summary>Women menopause transition ( 'perimenopause ' ) expose extreme hormone variability , tend experience unique set severe stressor ( e.g. , divorce , death love one ) , also substantially elevate risk suffer mood anxiety disorder . The purpose research understand mechanism variability estradiol ( E2 ) associate symptom anxiety anhedonia ( loss interest pleasure - common symptom depression ) . By stabilize E2 variability hormonal manipulation , research determine degree E2 variability ( E2 level ) play causal role perimenopausal anxiety anhedonia symptom whether affect biological response stress .</brief_summary>
	<brief_title>The Menopause Transition : Estrogen Variability , Stress Reactivity Mood</brief_title>
	<detailed_description>Framed within diathesis-stress model , primary objective research determine pathophysiological mechanism estradiol ( E2 ) clinical anxiety anhedonia see menopause transition ( MT ) . Specifically whether E2 variability E2 level predict exaggerate hypothalamic-pituitary-adrenal ( HPA ) axis reactivity impaired recovery stress , turn , deficits behavioral index threat responsivity approach motivation symptom anxiety anhedonia . The secondary objective research use hormonal manipulation mechanistic probe stabilize E2 variability premenopausal range determine : ) HPA axis reactivity/recovery represent biomarker behavioral symptom response E2 stabilization ; b ) whether recent severe life stress predict HPA axis response hormone stabilization . A total 170 woman early late MT eligible hormonal probe recruit reflect full continuum anxiety anhedonia symptom base self-report State-Trait Anxiety Inventory Snaith-Hamilton Pleasure Scale , respectively . However , investigator over-represent clinically impairing end anxious anhedonic phenotype ( 75 % sample ) . Over 8-week baseline , anxiety anhedonia symptom serum E2 measure liquid chromatography-tandem mass spectrometry ( LC-MS/MS ) assess weekly basis . At baseline week 8 , HPA axis ( plasma cortisol ACTH ) response Trier Social Stress Test behavioral measure threat responsivity ( via Dot-Probe task ) approach motivation ( Effort Expenditure Rewards Task 'EEfRT ' ) determine . Using transdermal E2 pharmacological probe stabilize variability E2 premenopausal range , woman randomize transdermal E2 ( 0.10 mg ) placebo 16 week . This clinical efficacy trial . The investigator use randomize control trial ( RCT ) design hormonal manipulation order investigate pathophysiologic role E2 variability ( E2 level ) HPA axis dysregulation , turn , threat responsivity approach motivation . Serum E2 assess weekly week 9-16 , HPA axis reactivity stress behavioral response Dot-Probe EEfRT task assess every four week 16 week probe .</detailed_description>
	<mesh_term>Stress , Psychological</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Perimenopausal ( either early perimenopause , define menstrual cycle length 7+ day longer short usual ; late perimenopause , define ≥2 skip cycle interval amenorrhea ≥60 day within one year last menstrual period ) 45 60 year age must medically healthy history cardiovascular disease ( CVD ) include coronary artery disease , arteriosclerosis , heart attack , stroke Type I II diabetes personal history thrombotic event personal family history suggest elevate risk E2related cancer currently experience migraine headache aura</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>perimenopause</keyword>
	<keyword>menopause transition</keyword>
	<keyword>estrogen</keyword>
	<keyword>stress</keyword>
	<keyword>mood</keyword>
</DOC>